معرفی
James Yarmolinsky is an Advanced Research Fellow in Molecular Epidemiology at the School of Public Health within the Faculty of Medicine at Imperial College London. His research focuses on leveraging human genetics to develop pharmacological interventions for chronic disease prevention and treatment, particularly exploring shared mechanisms between cardiometabolic diseases and cancer risk. He holds a PhD in Epidemiology from the University of Bristol (2020) and an MSc from the London School of Hygiene & Tropical Medicine, with prior work at the Brazilian Longitudinal Study of Adult Health in Porto Alegre, Brazil.
As Principal Investigator (PI) of a Cancer Research UK Prevention and Population Research Project, he investigates mechanisms linking adiposity to pancreatic cancer using genetic, observational, and molecular approaches. He also co-leads a Cancer Research UK Early Detection Primer Award using Reverse Mendelian Randomization to identify early cancer biomarkers.
Research interests include drug repurposing, biomarker discovery, and Mendelian randomization techniques to analyze causal relationships between biological factors and disease outcomes. His work spans oncology, cardiometabolic disorders, and public health, with a focus on translational applications.
- Grants: Cancer Research UK Prevention Award (2025–2028), Early Detection Primer Award (2025–2026)
- Education: PhD in Epidemiology (University of Bristol, 2020), MSc in Epidemiology (LSHTM, 2017)
Publications emphasize causal inference methodologies, with recent work on adiposity-cancer links, proteomic biomarkers, and drug target identification. Collaborative efforts with global cohorts (e.g., EPIC) and Mendelian randomization approaches highlight his focus on methodological rigor and translational impact.
